Adam J Gehring, PhD

Follow Dr. Gehring:
Scientist, Toronto General Hospital Research Institute (TGHRI)
 
https://orcid.org/0000-0003-1150-5840
Keywords: hepatitis B, immunology, immunotherapy, monocyte, liver, T cells
Adam Gehring received his Ph.D. at Case Western Reserve University in Cleveland, Ohio. His training included a Postdoctoral Fellowship in the Institute of Hepatology at University College London and a position of Senior Research Fellow, and subsequently Assistant Principal Investigator, at the Singapore Institute for Clinical Sciences. Dr. Gehring moved to Saint Louis University as an Assistant Professor in the Molecular Microbiology and Immunology department in March 2013 before joining the Toronto Centre for Liver Disease as Biology Lead in February 2016. 
My lab investigates the pathogenesis of chronic hepatitis B virus infection with the goal of exploiting that knowledge to develop novel immunotherapeutic approaches. I am particularly interested in how the human immune system interacts with viral proteins in the blood and immune responses in the human liver, the site of HBV infection.
 
My previous work demonstrated that specific immune cells, monocytes, in the blood of chronic hepatitis B patients internalize and retain viral antigen. Using a combination of cytokines we could stimulate presentation of the captured antigen to boost HBV-specific T cell immunity. The goal now is to further understand this mechanism in patients to define an immunotherapeutic drug combination that can be used to restore anti-viral T cell immunity using the personalized antigen reservoir in the patients’ blood.
 
Our research on human liver immunology focuses on how age, sex and infection impact the intrahepatic immune response.  Chronic hepatitis B is a progressive disease that worsens with age and men are more likely than women to develop liver cancer. We are trying to elucidate functional differences in the liver to understand HBV progression and biomarkers that could provide a drug targets to stop or slow disease progression.  

Related Links

Research Gate Profile
 
A global scientific strategy to cure hepatitis B.
Lancet Gastroenterol Hepatol. 2019 Apr 10;:
Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, Levrero M, Li W, Liang TJ, Lim SG, Lu F, Penicaud MC, Tavis JE, Thimme R, Members of the ICE-HBV Working Groups, ICE-HBV Stakeholders Group Chairs...
Host-pathogen interactions in chronic HBV infection and transplantation of HCV-positive organs.
Nat Rev Gastroenterol Hepatol. 2019 Jan 07;:
Feld JJ, Gehring AJ
New treatments to reach functional cure: Rationale and challenges for emerging immune-based therapies.
Best Pract Res Clin Gastroenterol. 2017 Jun;31(3):337-345
Gehring AJ
Type I Interferon Responses Drive Intrahepatic T cells to Promote Metabolic Syndrome.
Sci Immunol. 2017 Apr 21;2(10):
Ghazarian M, Revelo XS, Nøhr MK, Luck H, Zeng K, Lei H, Tsai S, Schroer SA, Park YJ, Chng MHY, Shen L, D'Angelo JA, Horton P, Chapman WC, Brockmeier D, Woo M, Engleman EG, Adeyi O, Hirano N, Jin T, Gehring AJ, Winer S, Winer DA
The role of innate immunity in the immunopathology and treatment of HBV infection.
J Hepatol. 2016 Apr;64(1 Suppl):S60-S70
Maini MK, Gehring AJ
Trained immunity in newborn infants of HBV-infected mothers.
Nat Commun. 2015;6:6588
Hong M, Sandalova E, Low D, Gehring AJ, Fieni S, Amadei B, Urbani S, Chong YS, Guccione E, Bertoletti A
Reply to: "To target or not to target viral antigens in HBV related HCC?".
J Hepatol. 2015 Jun;62(6):1450-2
Qasim W, Brunetto M, Gehring AJ, Maini MK, Bonino F, Stauss H, Bertoletti A
Dissecting the dendritic cell controversy in chronic hepatitis B virus infection.
Cell Mol Immunol. 2015 May;12(3):283-91
Gehring AJ, Ann D'Angelo J
Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient.
J Hepatol. 2015 Feb;62(2):486-91
Qasim W, Brunetto M, Gehring AJ, Xue SA, Schurich A, Khakpoor A, Zhan H, Ciccorossi P, Gilmour K, Cavallone D, Moriconi F, Farzhenah F, Mazzoni A, Chan L, Morris E, Thrasher A, Maini MK, Bonino F, Stauss H, Bertoletti A
A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.
PLoS One. 2014;9(7):e101904
King TH, Kemmler CB, Guo Z, Mann D, Lu Y, Coeshott C, Gehring AJ, Bertoletti A, Ho ZZ, Delaney W, Gaggar A, Subramanian GM, McHutchison JG, Shrivastava S, Lee YJ, Kottilil S, Bellgrau D, Rodell T, Apelian D

Pages